Gate Bioscience is a preclinical biotechnology company creating a new class of medicines called Molecular Gates. Molecular Gates are small molecule drugs that selectively eliminate harmful extracellular proteins at their origin: inside the cell. The company's mission is to eliminate diseases for patients by targeting disease-causing proteins through a completely new therapeutic mechanism.

Gate Bioscience

Gate Bioscience is a preclinical biotechnology company creating a new class of medicines called Molecular Gates. Molecular Gates are small molecule drugs that selectively eliminate harmful extracellular proteins at their origin: inside the cell. 

Humans produce over 4,000 distinct extracellular proteins, more than 1,000 of which can drive disease when they act improperly, misfold, or are made at the wrong time, in the wrong place, or at incorrect levels. By eliminating these disease-causing proteins, we aim to eliminate diseases for patients.

Molecular Gates act by a completely new therapeutic mechanism. All extracellular proteins pass through single channel in the cell as they are secreted into the body. Molecular Gates bind to this channel, setting up a “gate” that recognizes and blocks a specific, disease-causing protein from exiting. With nowhere to go, the harmful protein is degraded by the cell instead of being secreted.

Our mission to create Molecular Gate medicines is backed by Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. Learn more at www.gatebio.com.

As 2023 draws to a close, we're reflecting on the last 365 days of Gate Bioscience. We're proud of everything our exceptional team has accomplished, and we're profoundly grateful for everyone who's been a part of our journey so far. 

Thank you to all our employees, partners, collaborators, advisors, and investors who have contributed to Gate's momentum this year—and may your 2024 be full of exciting science, discoveries, and growth!

Tune into the Bio Eats World podcast to hear our CEO and cofounder Jordi Mata-Fink talk with Vineeta Agarwala, MD PhD and Ben Portney from a16z Bio + Health about Gate Bioscience and building a novel scientific platform. 

They get geeky about:

 🔬 Extracellular proteins and how they cause diseases
 💊 Why small molecules rock (or, as Vineeta calls them, "the OGs of our therapeutic arsenal")
 🤝 Bringing together the right team
 🚀 The power of a platform in drug discovery
 🍗 Gate's "barbecue of discovery"

Take a listen for all this and more wherever you get your favorite podcasts!

Looking for a podcast for your commute to or from work? 

Tune into Labiotech.eu's latest episode of Beyond Biotech to hear our CEO and Co-Founder, Jordi Mata-Fink, talk with Host Jim Cornall about Gate's science, the promise of Molecule Gate medicines for diseases driven by extracellular proteins, and our vision for this new class of medicines.

🔉 Listen: https://apple.co/3sSdO7f 🔉
🔬 Read more: https://bit.ly/3N3rCmp 🔬

Curious about Gate and our science? Lei Lei Wu has the details in Endpoints News today. 

Check out her article to hear more about the secretory translocon and the powerful potential of Molecular Gate medicines from our Co-Founder and CEO Jordi Mata-Fink and our BOD members and investors Vineeta Agarwala, MD PhD (a16z Bio + Health) and Clare Ozawa (Versant Ventures).

💊 🗞 Click to read more! 💊 🗞

Today’s a big day for Gate Bioscience—we’ve emerged from stealth, unveiling our science, Molecular Gate medicines, our platform, and $60M in funding from Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV (Google Ventures). Come take a look at our press release to learn more about our science, leadership team, and our vision for Molecular Gate medicines. 

https://lnkd.in/efRmE_zJ

Metric
Company Name	Gate Bioscience
Symbol
MSH ID	COM:GATEBIO
Market	PRIVATE
Sector	Healthcare
Industry	Biotechnology Research
Country	US
Stage
Employee Count	27
Website	gatebio.com
LinkedIn	gatebio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	577
Web Traffic Growth	-0.44
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	93.87
28-Day Growth Score	66.40
90-Day Growth Score	62.81
365-Day Growth Score	70.62

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:GATEBIO

Gate Bioscience

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue